We studied the occurrence of anti-hepatitis C (HCV) antibodies in patients with malignant disease (53), in patients undergoing haemodialysis (56), and in blood donors (204) as healthy population controls. The study was carried out using the second-generation EIA test. Anti-HCV positivity was 23.2% in haemodialysis (HD) patients, 0.5% in blood donors, and 0% of the patients with malignant disease (MD). There was no association between anti-HCV positivity and the results of AST, ALT and HBsAg tests in patients and controls. But there was significant association of blood transfusion frequency and duration of HD with anti-HCV positivity in patients undergoing HD, and conversely an absence of this association in patients with MD. However, two of the anti-HCV-positive HD patients did not have any blood transfusion history. One HCV-positive blood donor had a history of surgical operation. Nosocomial transmission of HCV infection has replaced blood transfusion as the main risk factor in HD patients, and preventive measures should be performed in this direction to control infection.
Journal Article Prevalence of anti-HCV among haemodialysis patients in Turkey: a multicentre study Get access T. Akpolat, T. Akpolat Ondokuz Mayis University School of MedicineSamsun, Turkey (organizing centre) Search for other works by this author on: Oxford Academic PubMed Google Scholar N. Arik, N. Arik Ondokuz Mayis University School of MedicineSamsun, Turkey (organizing centre) Search for other works by this author on: Oxford Academic PubMed Google Scholar M. Günaydin, M. Günaydin Ondokuz Mayis University School of MedicineSamsun, Turkey (organizing centre) Search for other works by this author on: Oxford Academic PubMed Google Scholar C. Utaş, C. Utaş Ondokuz Mayis University School of MedicineSamsun, Turkey (organizing centre) Search for other works by this author on: Oxford Academic PubMed Google Scholar K. Dilek, K. Dilek Ondokuz Mayis University School of MedicineSamsun, Turkey (organizing centre) Search for other works by this author on: Oxford Academic PubMed Google Scholar Ş. Çaglar, Ş. Çaglar Ondokuz Mayis University School of MedicineSamsun, Turkey (organizing centre) Search for other works by this author on: Oxford Academic PubMed Google Scholar F. Candan, F. Candan Ondokuz Mayis University School of MedicineSamsun, Turkey (organizing centre) Search for other works by this author on: Oxford Academic PubMed Google Scholar G. Süleymanlar, G. Süleymanlar Ondokuz Mayis University School of MedicineSamsun, Turkey (organizing centre) Search for other works by this author on: Oxford Academic PubMed Google Scholar S. Paydaş, S. Paydaş Ondokuz Mayis University School of MedicineSamsun, Turkey (organizing centre) Search for other works by this author on: Oxford Academic PubMed Google Scholar S. Şen, S. Şen Ondokuz Mayis University School of MedicineSamsun, Turkey (organizing centre) Search for other works by this author on: Oxford Academic PubMed Google Scholar ... Show more S. Kürşat, S. Kürşat Ondokuz Mayis University School of MedicineSamsun, Turkey (organizing centre) Search for other works by this author on: Oxford Academic PubMed Google Scholar M. Yeksan, M. Yeksan Ondokuz Mayis University School of MedicineSamsun, Turkey (organizing centre) Search for other works by this author on: Oxford Academic PubMed Google Scholar E. Akoglu, E. Akoglu Ondokuz Mayis University School of MedicineSamsun, Turkey (organizing centre) Search for other works by this author on: Oxford Academic PubMed Google Scholar M. Boran, M. Boran Ondokuz Mayis University School of MedicineSamsun, Turkey (organizing centre) Search for other works by this author on: Oxford Academic PubMed Google Scholar T. Arinsoy, T. Arinsoy Ondokuz Mayis University School of MedicineSamsun, Turkey (organizing centre) Search for other works by this author on: Oxford Academic PubMed Google Scholar S. Bozfakioglu, S. Bozfakioglu Ondokuz Mayis University School of MedicineSamsun, Turkey (organizing centre) Search for other works by this author on: Oxford Academic PubMed Google Scholar T. Çamsari, T. Çamsari Ondokuz Mayis University School of MedicineSamsun, Turkey (organizing centre) Search for other works by this author on: Oxford Academic PubMed Google Scholar Z. Tonbul, Z. Tonbul Ondokuz Mayis University School of MedicineSamsun, Turkey (organizing centre) Search for other works by this author on: Oxford Academic PubMed Google Scholar A. Vural, A. Vural Ondokuz Mayis University School of MedicineSamsun, Turkey (organizing centre) Search for other works by this author on: Oxford Academic PubMed Google Scholar R. Ataman R. Ataman Ondokuz Mayis University School of MedicineSamsun, Turkey (organizing centre) Search for other works by this author on: Oxford Academic PubMed Google Scholar Nephrology Dialysis Transplantation, Volume 10, Issue 4, April 1995, Pages 479–480, https://doi.org/10.1093/ndt/10.4.479 Published: 01 April 1995
Letters| May 02 2002 Detection of Hepatitis B and C Infection by Polymerase Chain Reaction among Hemodialysis Patients Subject Area: Nephrology E. Kocabas; E. Kocabas bPediatric Infection and Search for other works by this author on: This Site PubMed Google Scholar N. Seyrek; N. Seyrek aDepartment of Nephrology, Search for other works by this author on: This Site PubMed Google Scholar S. Paydas; S. Paydas aDepartment of Nephrology, Search for other works by this author on: This Site PubMed Google Scholar F. Köksal; F. Köksal cMicrobiology, Çukurova University Medical Faculty, Adana, Turkey Search for other works by this author on: This Site PubMed Google Scholar I. Karayaylalı; I. Karayaylalı aDepartment of Nephrology, Search for other works by this author on: This Site PubMed Google Scholar N. Aksaray; N. Aksaray bPediatric Infection and Search for other works by this author on: This Site PubMed Google Scholar Y. Saglıker Y. Saglıker aDepartment of Nephrology, Search for other works by this author on: This Site PubMed Google Scholar Nephron (2002) 91 (1): 178–180. https://doi.org/10.1159/000057627 Article history Published Online: May 02 2002 Content Tools Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation E. Kocabas, N. Seyrek, S. Paydas, F. Köksal, I. Karayaylalı, N. Aksaray, Y. Saglıker; Detection of Hepatitis B and C Infection by Polymerase Chain Reaction among Hemodialysis Patients. Nephron 1 May 2002; 91 (1): 178–180. https://doi.org/10.1159/000057627 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsNephron Search Advanced Search Article PDF first page preview Close Modal 2002Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. You do not currently have access to this content.
Background: Real-life studies of moderate size have shown satisfactory but less impressive results compared with the initial study of R-da-EPOCH in PMLBCL. However, the strategies regarding the use of consolidative radiotherapy (RT) and the compliance with the strict instructions on dose escalation have not been studied. Aims: To assess the clinical outcomes and prognostic factors after R-da-EPOCH, the use of consolidative RT and protocol compliance in a multinational real-life setting. Methods: 225 patients (≤60 years) were enrolled from 18 Greek (n=114), 6 Israeli (n=57), 6 Turkish (n=34) and a single Saudi Arabia center (n=20). Consolidative RT was given at the treating physician’s discretion and was highly affected by PET/CT results. Results: The median age of the patients was 33 years (16-60), 139 (62%) were females, 40% had B-symptoms, 32% extranodal involvement (E or stage IV), 18% PS≥2, 84% elevated LDH (35% highly elevated≥2xnormal). The median follow-up was 32.5 months (2-97). Among 200 evaluable patients with conventional response, who would be potentially eligible for RT, RT was spared in 169 (84%); 31 received RT mainly for Deauville 4 (or rarely Deauville 5) residuals. The 5-year Freedom From Progression (FFP) was 86%. However, 4 patients developed therapy-related (t-) AML at 10.5-22 months from treatment initiation, while in 1st remission, and one Hodgkin lymphoma, for a 2-year event-free survival of 83%, if considered as events. The 5-year overall survival (OS) was 92% with 14 disease-related deaths (1 toxic). Protocol violations were common (52%), mainly consisting of insufficient dose escalation despite the absence of prohibitive toxicity. Among 209 patients with available data, 58% reached level ≥3 and 29% ≥4 (73% and 46% among those with strict protocol adherence). The 5-year FFP was 89% vs 84% for patients with strict protocol adherence or not (p=0.37); OS was not also different. FFP did not differ according to the final level reached (≥3 or ≥4; both p>0.20). A more detailed analysis of outcome according to the degree of protocol violations is currently ongoing. The prognostic systems including any extranodal involvement (E/IV) and highly elevated LDH (≥2x) or bulk marginally or significantly affected prognosis: Considering the E/IV-LDH model, the 5-year FFP was 89%, 84% and 73% for patients with 0, 1 or 2 adverse factors (p=0.14), while 5-year OS was 97%, 91% and 81% (p=0.08). The corresponding figures for the E/IV-bulk model were 90%, 89% and 75% (p=0.026) for FFP and 98%, 94% and 83% for OS (p=0.01). Thus, patients with both risk factors had 5-year FFP rates 73-75% and 5-year OS 81-83%. Summary/Conclusion: In the largest series reported so far for R-da-EPOCH in PMLBCL, FFP appeared somewhat but not impressively better than the expected with R-CHOP. However, consolidative RT was safely omitted in ~85% of responders mainly based on PET findings. OS was 92%. However, the appearance of 4 cases of t-AML among 225 patients is worrisome. Significant dose-escalation violations were recorded in the real-life; their impact on outcomes appears to be modest and is further evaluated in detail while the series is also expanded with inclusion of even more patients. Patients with multiple adverse factors appear to do better than with R-CHOP, while those with 0-1 factor have similar outcomes to R-CHOP but with minimal consolidative RT.
Anti-hepatitis C virus (HCV) antibody prevalence was investigated in 228 patients with lymphoproliferative disorders (LPDs). Twenty-six of 228 (11.40%) patients with LPDs were positive for anti-HCV which was higher than the donor population (P = 0.0007). Nine of 98 cases with non-Hodgkin's lymphoma, five of 47 cases with multiple myeloma, seven of 36 cases with Hodgkin's disease, four of 38 cases with chronic lymphocytic leukaemia and one of nine cases with acute lymphoblastic leukaemia had anti-HCV antibody. In all patients, odds ratio (OR) for anti-HCV was 24.09. This value was higher in patients less than 35 years as 62.04 for below 25 years and 32.00 for between 25-35 years. Our findings suggest that HCV infection might be a causative and/or contributing factor in lymphoproliferation.
